

Receipt date: 12/18/2006

10589054 - GAU: 1646

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 5

Complete if Known

Application Number	10/589,054
Filing Date	February 11, 2005
First Named Inventor	SOARES, et al
Art Unit	4744 1646
Examiner Name	Not Yet Assigned Zachary C. Howard
Attorney Docket Number	0105US-UTL2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US- 2003-0026182	02-06-2003	FISCHER, et al	
	002	US- 2003-0092606	05-15-2003	L'ITALIEN, et al	
	003	US- 2004-0022807	02-05-2004	DUFT, et al	
	004	US- 2006-0094652	05-04-2006	LEVY, et al	
	005	US- 2006-0094653	05-04-2006	LEVY, et al	
	006	US- 2006-0135747	06-22-2006	LEVY, et al	
	007	US- 5,124,314	06-23-1992	COOPER	
	008	US- 5,264,372	11-23-1993	BEAUMONT, et al	
	009	US- 5,578,708	11-26-1996	OKAZAKI, et al	
	010	US- 5,686,411	11-11-1997	GAETA, et al	
	011	US- 5,766,627	06-16-1998	SANKARAM, et al	
	012	US- 5,998,367	12-07-1999	GAETA, et al	
	013	US- 6,087,334	07-11-2000	BEELEY, et al	
	014	US- 6,114,304	09-05-2000	KOLTERMAN, et al	
	015	US- 6,143,718	11-07-2000	KOLTERMAN, et al	
	016	US- 6,296,842	10-02-2001	JAWOROWICZ, et al	
	017	US- 6,368,630	04-09-2002	BERNSTEIN, et al	
	018	US- 6,379,703	04-30-2002	LYONS, et al	
	019	US- 6,379,704	04-30-2002	WRIGHT, et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	020	EP 289287	01-28-1998	COOPER, et al		
	021	WO 2005/000222	01-06-2005	ONG, et al		
	022	WO 94/26292	11-24-1994	BALASUBRAMANIAM		
	023	WO 96/40196	12-19-1996	RINK, et al		
	024	WO 99/07404	02-18-1999	BEELEY, et al		
	025	WO 99/25727	05-27-1999	BEELEY, et al		

Examiner
Signature

/Zachary Howard/

Date
Considered

05/03/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 5

Complete if Known

Application Number	10/589,054
Filing Date	February 11, 2005
First Named Inventor	SOARES, et al
Art Unit	1744
Examiner Name	Not Yet Assigned
Attorney Docket Number	0105US-UTL2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	026	US- 6,410,511	06-25-2002	L'ITALIEN, et al	
	027	US- 6,458,387	10-01-2002	SCOTT, et al	
	028	US- 6,610,824	08-26-2003	GAETA, et al	
	029	US- 6,936,584	08-30-2005	BEELEY, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	030	WO 99/25728	05-27-1999	BEELEY, et al		
	031	WO 99/40928	08-19-1999	BEELEY, et al		
	032	WO 05/77072	08-25-2005	LEVY, et al		
	033	WO 05/77094	08-25-2005	LEVY, et al		
	034	WO 06/66024	06-22-2006	LEVY, et al		

Examiner
Signature

/Zachary Howard/

Date
Considered

05/03/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 3	of 5	Attorney Docket Number 0105US-UTL2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	035	BECKER, "Procalcitonin and the Calcitonin Gene Family of Peptides..." J. Clin. Endocrinology & Metabolism, 89(4):1512-1525 (2004)	
	036	BECK-SICKINGER, et al "Complete L-alanine Scan of Neuropeptide Y Reveals Ligands Binding..." Eur. J. Biochem., 223:947-958 (1994)	
	037	BRAY, GA, "Drug Treatment of Obesity", Am. J. Clin. Nutr., 55:538S-544S (1992)	
	038	BRAY, GA, "Treatment for Obesity: A Nutrient Balance/Nutrient Partition Approach" Nutr. Rev. 49:33-45 (1991)	
	039	CAMPFIELD, LA, "Recombinant Mouse OB Protein:Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks" Science, 269:546-549 (1995)	
	040	GIBBS, et al. "Rational Scanning Mutagenesis of a Protein Kinase Identifies Functional Regions Involved in Catalysis and Substrate..." J. Biol. Chem., 266:8923-8931 (1991)	
	041	HALAAS, JL, "Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene" Science, 269:543-546 (1995)	
	042	HILTON, JM, et al "Identification of Key Components in the Irreversibility of Salmon Calcitonin Receptors" The Journal of Endocrinology, Vol. 166, No. 1, pgs 213-226 Jul 2000	
	043	JUNG, RT, "The Management of Obesity" Clin. Endocrinol. (Oxf.) 35:11-20 (1991)	
	044	KUCZMARSKI, "Prevalence of Overweight and Weight Gain in the United States" Amer. J. of Clin. Nut., 55:495S-502S (1992)	

Examiner Signature	/Zachary Howard/	Date Considered	05/03/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 4	of 5	Attorney Docket Number	0105US-UTL2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	045	KUESTNER, RE, "Cloning and Characterization of an Abundant Subtype of the Human Calcitonin Receptor" Mol. Pharmacol., 46:246-255 (1994)	
	046	KURIHARA, H, "Targeted Disruption of Adrenomedullin and alphaCGRP Genes Reveals Their Distinct Biological Roles" Hypertens Res., 26 Suppl S (Feb 2003)	
	047	LEE, et al, "Successful Weight Loss with Protein-Sparing Modified Fast in a Morbidly Obese Boy..." Clin. Pediatr. 31:234-236 (April 1992)	
	048	LYZNICKI, JM, "Obesity: Assessment and Management in Primary Care" Am. Fam. Physician, 63:2185-2196 (2001)	
	049	MATSUSHITA, et al, "Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin..." J. Biol. Chem., 275:11044-11049 (2000)	
	050	MORLEY, et al "Modulation of Food Intake by Peripherally Administered Amylin" Am. J. Physiol. 267:R178-R184 (1994)	
	051	MORRISON, et al "Combinatorial Alanine-Scanning" Curr. Opin. Chem. Biol. 5:302-307 (2001)	
	052	MUFF, et al "Comparison of a Calcitonin Gene-related Peptide Receptor in a Human Neuroblastoma Cell Line..." Ann. NY Acad. Sci. 657:106-116 (1992)	
	053	PELLEYMOUNTER, et al "Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice" Science 269:540-543 (1995)	
	054	POYNER, et al "Structural Determinants for Binding to CGRP Receptors Expressed by Human SK-N-MC and Col 29 Cells..." British J. of Pharm. 124(8):659-1666 (1998)	

Examiner Signature	/Zachary Howard/	Date Considered	05/03/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 5	of 5	Attorney Docket Number	0105US-UTL2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	055	REEDER, et al "Obesity and its Relation to Cardiovascular Disease Risk Factors in Canadian Adults" Can. Med. Assoc. J. 146(11):2009-2019 (1992)	
	056	RISSANEN, et al "Risk of Disability and Mortality Due to Overweight in a Finnish Population" BMJ 301:835-837 (1990)	
	057	SANDBERG, et al "New Chemical Descriptors Relevant for the Design of Biologically Active Peptides..." J. Med. Chem.41:2481-2491 (1998)	
	058	SEXTON, et al "Calcitonin" Current Medicinal Chemistry 6:1067-1093 (1999)	
	059	SURWIT, et al "Differential Effects of Fat and Sucrose on the Development of Obesity and Diabetes..." Metabolism 44:645-651 (1995)	
	060	WEINTRAUB, et al "Drug Treatment of Obesity" Medical Clinics of North America 73(1):237 (1989)	
	061	WIMALAWANSA "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily" Crit. Rev. Neurobiol. 11:167-239 (1997)	

Examiner Signature	/Zachary Howard/	Date Considered	05/03/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./